Aristotle Capital Management’s Novartis NVS Stock Holding History

Aristotle Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,794	Closed	-$206K	–	186
2024 Q3	$206K	Sell	1,794 -178	-9%	-$20.2K	﹤0.01%	183
2024 Q2	$210K	Sell	1,972 -444,417	-100%	-$44.6M	﹤0.01%	177
2024 Q1	$43.2M	Sell	446,389 -145,946	-25%	-$15M	0.08%	108
2023 Q4	$59.8M	Buy	592,335 +2,979	+0.5%	+$288K	0.12%	91
2023 Q3	$60M	Buy	589,356 +2,594	+0.4%	+$263K	0.13%	87
2023 Q2	$59.2M	Buy	586,762 +15,635	+3%	+$1.56M	0.12%	94
2023 Q1	$52.5M	Buy	571,127 +7,754	+1%	+$677K	0.11%	98
2022 Q4	$51.1M	Sell	563,373 -22,494	-4%	-$1.89M	0.11%	98
2022 Q3	$44.5M	Sell	585,867 -9,205	-2%	-$763K	0.1%	97
2022 Q2	$50.3M	Buy	595,072 +9,583	+2%	+$841K	0.11%	93
2022 Q1	$51.4M	Buy	585,489 +23,280	+4%	+$2.02M	0.09%	97
2021 Q4	$49.2M	Sell	562,209 -7,565,477	-93%	-$628M	0.08%	95
2021 Q3	$665M	Buy	8,127,686 +61,589	+0.8%	+$5.54M	1.26%	37
2021 Q2	$736M	Buy	8,066,097 +157,444	+2%	+$14M	1.41%	36
2021 Q1	$676M	Buy	7,908,653 +790,589	+11%	+$70.9M	1.38%	39
2020 Q4	$672M	Buy	7,118,064 +358,571	+5%	+$31.3M	1.67%	29
2020 Q3	$588M	Buy	6,759,493 +190,861	+3%	+$16.5M	1.78%	29
2020 Q2	$574M	Buy	6,568,632 +685,903	+12%	+$59.2M	1.93%	25
2020 Q1	$485M	Buy	5,882,729 +94,561	+2%	+$8.44M	2.05%	21
2019 Q4	$548M	Buy	5,788,168 +2,277,806	+65%	+$204M	1.8%	28
2019 Q3	$305M	Buy	3,510,362 +113,682	+3%	+$10.2M	1.62%	31
2019 Q2	$310M	Sell	3,396,680 -509,414	-13%	-$43.1M	1.73%	31
2019 Q1	$336M	Buy	3,906,094 +481,921	+14%	+$38.7M	2%	26
2018 Q4	$263M	Sell	3,424,173 -660,688	-16%	-$51.4M	1.78%	32
2018 Q3	$315M	Sell	4,084,861 -26,528	-0.6%	-$1.96M	1.84%	32
2018 Q2	$278M	Buy	4,111,389 +317,390	+8%	+$21.9M	1.71%	35
2018 Q1	$275M	Buy	3,793,999 +228,229	+6%	+$17.4M	1.85%	29
2017 Q4	$268M	Buy	3,565,770 +240,592	+7%	+$18.2M	1.86%	28
2017 Q3	$256M	Sell	3,325,178 -9,678	-0.3%	-$731K	1.99%	28
2017 Q2	$249M	Buy	3,334,856 +127,970	+4%	+$9.07M	2.08%	24
2017 Q1	$213M	Buy	3,206,886 +125,162	+4%	+$8.34M	1.94%	30
2016 Q4	$201M	Buy	3,081,724 +50,257	+2%	+$3.26M	1.9%	32
2016 Q3	$214M	Sell	3,031,467 -23,242	-0.8%	-$1.69M	2.23%	26
2016 Q2	$226M	Buy	3,054,709 +739,183	+32%	+$51.1M	2.45%	17
2016 Q1	$150M	Buy	2,315,526 +209,288	+10%	+$14.2M	1.74%	32
2015 Q4	$162M	Buy	2,106,238 +83,025	+4%	+$6.6M	1.96%	26
2015 Q3	$167M	Buy	2,023,213 +10,337	+0.5%	+$920K	2.08%	26
2015 Q2	$177M	Buy	2,012,876 +25,777	+1%	+$2.36M	2.09%	26
2015 Q1	$176M	Buy	1,987,099 +1,822,962	+1,111%	+$162M	2.18%	24
2014 Q4	$13.6M	Buy	164,137 +5,043	+3%	+$418K	0.17%	50
2014 Q3	$13.4M	Buy	159,094 +13,665	+9%	+$1.11M	0.18%	49
2014 Q2	$11.8M	Sell	145,429 -81,004	-36%	-$6.37M	0.16%	74
2014 Q1	$17.3M	Buy	226,433 +87,000	+62%	+$6.34M	0.25%	54
2013 Q4	$10M	Buy	139,433 +75,577	+118%	+$5.25M	0.16%	58
2013 Q3	$4.39M	Buy	63,856 +30,428	+91%	+$2.01M	0.09%	66
2013 Q2	$2.12M	Buy	+33,428	New	+$2.17M	0.06%	73

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Aristotle Capital Management's NVS Position: Q4 2024 in Review

Aristotle Capital Management sold out of Novartis (NVS) in Q4 2024, closing a stake of 1,794 shares — an estimated $206K sold.

Aristotle Capital Management first reported a position in NVS in Q2 2013 and held it in 46 quarters. The position peaked at $736M in Q2 2021. 1,340 funds tracked by Wall St. Rank hold NVS as of Q4 2024.

Aristotle Capital Management reported no remaining Novartis position as of Q4 2024 after selling out during the quarter.
Aristotle Capital Management sold 1,794 Novartis shares in Q4 2024, an estimated $206K.
Aristotle Capital Management first reported a position in Novartis in Q2 2013 and held it in 46 quarters.
Aristotle Capital Management's Novartis position peaked at $736M in Q2 2021.
1,340 funds tracked by Wall St. Rank held Novartis as of Q4 2024.

Based on Aristotle Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.